Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
Top Cited Papers
- 1 August 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 44 (12), 2117-2136
- https://doi.org/10.1007/s00259-017-3780-7
Abstract
The rapidly expanding clinical adaptation of prostate-specific membrane antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has placed an increasing onus on understanding both the potential pearls of interpretation as well as limitations of this new technique. As with any new molecular imaging modality, accurate characterization of abnormalities on PSMA-targeted PET imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants of radiotracer uptake, and potential sources of false-positive and false-negative imaging findings. In recent years, a growing number of reports have come to light describing incidental non-prostatic benign or malignant pathologies with high uptake on PSMA-targeted PET imaging. In this review, we have summarized the published literature regarding the potential pearls and technical and interpretive pitfalls of this imaging modality. Knowledge of these limitations can increase the confidence of interpreting physicians and thus improve patient care.Keywords
This publication has 176 references indexed in Scilit:
- PSMA as a target for radiolabelled small moleculesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Challenges in Recognizing Treatment-Related Neuroendocrine Prostate CancerJournal of Clinical Oncology, 2012
- Effect of Paget’s disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasisBritish Journal of Cancer, 2012
- 2-(3-{1-Carboxy-5-[(6-[F-18]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [F-18]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate CancerClinical Cancer Research, 2011
- 123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane TherapyJournal of Nuclear Medicine, 2011
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenProceedings of the National Academy of Sciences of the United States of America, 2011
- Imaging metastatic bone disease from carcinoma of the prostateBritish Journal of Cancer, 2009
- Prostate-specific membrane antigen expression in regeneration and repairLaboratory Investigation, 2008
- Expression of prostate-specific membrane antigen in renal cortical tumorsLaboratory Investigation, 2008
- N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate CancerClinical Cancer Research, 2008